DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
When something we published turns out to be wrong, we fix it and say so here: what it said, what the primary source says, and which pages changed.
A correction is any change to a fact we stated — a price, a trial result, a date, a regulatory action. Wording and layout changes are not listed here; they are in the changelog. Found an error? Email [email protected] with the page and the source that contradicts it.
The most important corrections: semaglutide raises levothyroxine exposure (by 33%, per the FDA label) — an earlier answer said the opposite and suggested raising the dose; pre-surgery guidance now follows the 2024 multi-society recommendation that most patients continue their GLP-1; a claim that generic semaglutide is sold in Mexico was removed (none is approved there, and the claim could steer readers to counterfeit product); an invented lipedema study was replaced with the real five-patient case series; side-effect rates on comparison and drug pages now match the FDA labels. Figures we could not trace to a source were removed rather than kept.
Earlier versions of the index included price points that no manufacturer program ever charged: “direct” prices for Wegovy and Ozempic from before NovoCare sold them, a Mounjaro self-pay series, and a compounded-telehealth series. Every price change in the index now links to the manufacturer announcement that set it. If you cited the old index, please update the figures.
Six items in our news feed described events that did not happen — among them a “May 2026” end to the Wegovy shortage (the FDA resolved it on February 21, 2025), a CMS final rule on Medicaid coverage, and a four-year SELECT follow-up paper. Three more had wrong dates, doses or prices. The feed now carries only events that link to their primary source.
Ozempic self-pay was listed at $499 (it has been $349 for the 0.25–1 mg doses since November 17, 2025); Zepbound’s list price at $1,349 (it is about $1,087); Mounjaro at $1,025 list and $549 through LillyDirect (it is about $1,112 list, with cash-pay from $499 via TrumpRx). A weekly check now compares our prices with the manufacturers’ own pages.
Insurance-appeal overturn rates (now KFF data), reflux and nausea rates (now FDA-label figures), the Wegovy MASH approval date (August 15, 2025, not March 2026), a claim that ESSENCE covered F1 fibrosis (it enrolled F2–F3 only), bariatric-regain and PCOS figures, and the FDA’s count of adverse-event reports for compounded GLP-1s.
Four page templates stamped the build date into their structured data as the “last reviewed” date, which asserted a review that had not happened. Pages now carry a review date only when the content was actually re-checked.
These pages showed the current date as their last-updated date on every visit, whether or not anything on them had changed. The stamps were removed; pages driven by live data show when that data last changed.
An audit found patient testimonials and review scores we could not trace to any source, three claims that regulators had taken action against named telehealth companies (none could be verified), trial results attributed to the wrong studies in FAQ answers, citations that linked to publisher homepages instead of papers, and an FDA warning-letter feed with invented entries. All were removed or replaced with sourced figures, and our data types now require a source link for any regulatory action.
A homepage strip suggested that major news outlets had cited our research. They had not. It was replaced with a list of the primary sources we actually cite — FDA labels, NEJM, JAMA, The Lancet, Cochrane and ClinicalTrials.gov.
Earlier versions of the site credited reviews to named, board-certified clinicians, in bylines and in structured data. They were not real people. Every such byline and credential was removed; we now describe what we actually do — check claims against FDA labels and peer-reviewed trials. Some bylines reappeared through a data re-import and were removed again on June 14, 2026.